newsfilter
← Latest News
GlobeNewswire·

Cellectis Announces 2026 Strategy and Catalysts

NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies,